APA (7th ed.) Citation

XY, H., GM, S., ZT, Z., HC, S., F, L., Y, J., . . . J, Z. (2025). Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: A randomized, open, two-cohort Phase 2 Study. BMC medicine, 23(1), 573. https://doi.org/10.1186/s12916-025-04404-4

Chicago Style (17th ed.) Citation

XY, Huang, et al. "Anti-PD1 Antibody Toripalimab Combined with Lenvatinib, or GEMOX Chemotherapy Combined with Lenvatinib as First-line Therapy in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized, Open, Two-cohort Phase 2 Study." BMC Medicine 23, no. 1 (2025): 573. https://doi.org/10.1186/s12916-025-04404-4.

MLA (9th ed.) Citation

XY, Huang, et al. "Anti-PD1 Antibody Toripalimab Combined with Lenvatinib, or GEMOX Chemotherapy Combined with Lenvatinib as First-line Therapy in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized, Open, Two-cohort Phase 2 Study." BMC Medicine, vol. 23, no. 1, 2025, p. 573, https://doi.org/10.1186/s12916-025-04404-4.